Carboplatin, Ifosfamide, and Etoposide for Small Cell Lung Cancer
Author Information
Author(s): N. Thatcher, M. Lind, R. Stout, C. Payne, K.B. Carroll, C. Campbell, H. Moussalli
Primary Institution: Christie Hospital and Holt Radium Institute
Hypothesis
The combination of carboplatin, ifosfamide, and etoposide with vincristine and thoracic radiotherapy is effective for treating limited stage small cell lung cancer.
Conclusion
The treatment resulted in a 57% complete response rate and a median survival of 14 months for patients with small cell lung cancer.
Supporting Evidence
- 24 patients (57%) achieved a complete response one month after treatment.
- The median survival of the total group was 14 months.
- The actuarial 2-year survival rate was 37%.
Takeaway
Doctors used a mix of medicines to help people with a type of lung cancer, and many got better for a while.
Methodology
Forty-two patients were treated with a combination of carboplatin, ifosfamide, etoposide, and vincristine, followed by thoracic radiotherapy.
Limitations
The study had a small sample size and included patients with varying stages of cancer.
Participant Demographics
28 men and 14 women, median age 54 years (range 38-70).
Statistical Information
Confidence Interval
95% confidence limits for 2-year survival are 21.5-50.1.
Want to read the original?
Access the complete publication on the publisher's website